Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 11Recruiting 10Completed 7Unknown 4Withdrawn 3Terminated 3Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 3Erlotinib Hydrochloride 3surufatinib 2gallium Ga 68 dotatate 2dactolisib 2Sunitinib 2Magnetic Resonance Spectroscopy 2trifluridine tipiracil drug combination 1tislelizumab 1telotristat ethyl 1telotristat 1pertuzumab 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1lanreotide 1fosbretabulin 1entinostat 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Temozolomide 1Surveys and Questionnaires 1Somatostatin 1Serotonin 1Quality of Life 1Positron Emission Tomography Computed Tomography 1Panobinostat 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Neuroendocrine Tumors × lutetium Lu 177 dotatate × Clear all
NCT05987176 2026-01-14

NELMAS

Imperial College London

Phase 2 Terminated
1 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT07012330 2025-06-10

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Erasmus Medical Center

Phase 2 Terminated
111 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT02489604 2025-01-13

LUNET

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated
70 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡